All In Biotech

Drug Trial Radar · NCT05531682

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Oct 25, 2022

Primary completion

May 23, 2023

Study completion Jan 4, 2024

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • PlaceboOther

    Subjects will receive several injections of Placebo

  • HB0017Drug

    Subjects will receive HB0017 in different dosing regimens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PASI 90 responseTime frame: Week 12
  2. sPGA 0/1 responseTime frame: Week 12

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • The first hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, China

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • Skin Disease Hospital of Shandong First Medical University

    Jinan, Shandong, China

  • Yantai Yuhuangding hospital

    Yantai, Shandong, China

  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The Third People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.